About this trial
The objective of this study is to ascertain the diagnostic threshold of end-tidal carbon monoxide (ETCOc, adjusted for ambient CO levels) within the first three days postpartum, stratified by neonatal age at birth. Additionally, the study aims to evaluate the concordance of the risk range of ETCOc, as measured by non-dispersive infrared spectroscopy, with existing literature, and to assess the reliability of this technology in the management of neonatal hyperbilirubinemia.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Newborns with gestational age of ≥ 37 weeks and birth weight of ≥ 2.5 kg;
Newborns delivered by either vaginal delivery or cesarean section and with hospital stay of ≥ 3 days.
Disqualifiers
History of second-hand smoke exposure within 24 hours
Parents smoke or are exposed to second-hand smoke.
Trial design
Single group
Treatments tested in this trial
Erythrocyte Life Span Tester
DeviceThe non-dispersive infrared spectroscopy technique was employed to measure the end-tidal carbon monoxide (ETCOc) levels in newborns at intervals of 12, 24, 48, and 72 hours post-birth.
Treatment groups
Trial outcomes
Primary outcomes
The ETCOc values of newborns were measured, and the optimal ETCOc threshold values between different time points of the TSB group were obtained.
Establish an ETCOc diagnostic threshold for assessing the risk of hyperbilirubinemia in the early postnatal period based on the infant's age at birth. Determine the reliability and repeatability of ETCOc detection using non-dispersive infrared spectroscopy technology.Compare the concentrations of ETCOc between different groups and employ the ROC curve method to ascertain the optimal cut-off values of ETCOc at various time points across the TSB groups.
The ETCOc values of newborns
The ETCOc values of newborns were measured, and the optimal ETCOc threshold values between different time points of the TSB group were obtained.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.